Home / Business / Archive by category Bio & Healthcare (Page 9)

Archive by category Bio & Healthcare

Pharmaceutical Firms Focus on Convenient Diabetes and Obesity Drugs

SEOUL, Aug. 14 (Korea Bizwire) — South Korean pharmaceutical companies, currently involved in developing drugs for diabetes and obesity, are emphasizing the improvement of usage convenience by extending drug efficacy durations and modifying formulations. Peptron Inc. is progressing toward transferring PT404, a sustained-release diabetes and obesity treatment formulation, to global pharmaceutical firms. Unlike existing treatments [...]

Hyundai Bioscience, U.S. NIH to Co-develop Broad-spectrum Antiviral Drug

SEOUL, Aug. 13 (Korea Bizwire) — Hyundai Bioscience Co. said Sunday it will develop a broad-spectrum antiviral drug with the U.S. National Institutes of Health (NIH), a federal agency for conducting and supporting medical research. Hyundai Bioscience USA, a wholly owned subsidiary of Hyundai Bioscience Co., signed a Non-Clinical Evaluation Agreement (NCEA) with the National [...]

SK Biopharmaceuticals Q2 Net Loss Narrows on Robust Sales

SEOUL, Aug. 10 (Korea Bizwire) — SK Biopharmaceuticals Co., a biopharmaceutical affiliate of SK Group, said Thursday its net loss narrowed in the second quarter from a year earlier thanks to stellar overseas sales of its flagship epilepsy medication. Its net deficit for the April-June period reached 23.3 billion won (US$17.7 million) on a consolidated [...]

SK bioscience Buys 6.5 mln Shares in Novavax to Extend Partnership

SEOUL, Aug. 9 (Korea Bizwire) – SK bioscience Co., a pharmaceutical affiliate under South Korea’s SK Group, said Wednesday it has purchased 6.5 million shares in the U.S.-based biotechnology company Novavax Inc. for 110 billion won (US$83.4 million). With the stock purchase, SK bioscience will hold a 6.5 percent share in Novavax, according to the [...]

South Korea’s IT Giants Enter Non-Face-to-Face Healthcare Market

SEOUL, Aug. 8 (Korea Bizwire) — South Korea’s major IT companies are venturing into the non-face-to-face healthcare market in the latter half of this year. Local telecom giant KT Corp. finalized the trademark registration for KT MyCare, a remote care service catering to chronic conditions like diabetes, with the Korean Intellectual Property Office at the [...]

Samsung Bioepis Said to Acquire U.S. Biogen’s Biosimilar Unit

SEOUL, Aug. 2 (Korea Bizwire) — Samsung Bioepis Co., a biosimilar medicine developer under Samsung Group, has been in talks with Biogen Inc. to buy the U.S. biotech firm’s biosimilar business unit, industry sources said Wednesday. Through the deal with the Nasdaq-listed firm, Samsung Bioepis seeks to secure a direct sales network in the United [...]

SK Biopharmaceuticals Expects US$1 bln in U.S. Sales in 2029

SEOUL, July 18 (Korea Bizwire) — SK Biopharmaceuticals Co., a pharmaceutical affiliate of South Korea’s SK Group, said Tuesday that its signature anti-epilepsy treatment, Xcopri, could generate US$1 billion in sales in the United States in 2029. Xcopri, or cenobamate, is a medication for partial-onset seizures in adults discovered by SK Biopharmaceuticals and its U.S. [...]

Samsung Biologics Inks US$390.9 mln Manufacturing Deal with Novartis

SEOUL, July 10 (Korea Bizwire) — Samsung Biologics Co., the biotech arm of South Korea’s Samsung Group, said Monday it has signed a US$390.9 million deal with Novartis Pharma AG to manufacture the Switzerland-based pharmaceutical firm’s products. It is the final contract for an investment letter of intent announced in June last year, in which [...]

SK bioscience to Help Thailand Set Up Infrastructure for Vaccine Manufacturing

SEOUL, July 5 (Korea Bizwire) — SK bioscience Co., a pharmaceutical affiliate of South Korea’s SK Group, said Wednesday it has joined hands with Thailand’s state-run drugmaker to build vaccine manufacturing and development infrastructure in the Southeast Asian country. SK bioscience and Thailand’s Government Pharmaceutical Organization (GPO) signed a memorandum of understanding (MOU) on Tuesday, [...]

Samsung Biologics Seals US$1.08 bln Manufacturing Deals with Pfizer

SEOUL, July 4 (Korea Bizwire) — Samsung Biologics Co., the biotech arm of South Korea’s Samsung Group, said Monday it has sealed a combined US$1.08 billion partnership contracts with U.S. pharmaceutical giant Pfizer so far this year. The Korean company said it signed a new contract with Pfizer, a follow-up to the bilateral deal set [...]